(Q67898813)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1826961%20AND%20SRC:MED&resulttype=core&format=json

19 September 2019

title

Clinical trials with etanidazole (SR-2508) by the Radiation Therapy Oncology Group (RTOG) (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1826961%20AND%20SRC:MED&resulttype=core&format=json

19 September 2019

Clinical trials with etanidazole (SR-2508) by the radiation therapy oncology group (RTOG) (English)

1 reference

https://api.crossref.org/works/10.1016/0167-8140(91)90200-Z

3 December 2022

1 reference

https://api.crossref.org/works/10.1016/0167-8140(91)90200-Z

3 December 2022

author name string

T. H. Wasserman

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1826961

3 December 2022

D. J. Lee

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1826961

3 December 2022

D. Cosmatos

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1826961

3 December 2022

N. Coleman

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1826961

3 December 2022

T. Phillips

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1826961

3 December 2022

L. Davis

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1826961

3 December 2022

V. Marcial

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1826961

3 December 2022

J. Stetz

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1826961

3 December 2022

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=1826961

3 December 2022

publication date

1 January 1991

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1826961%20AND%20SRC:MED&resulttype=core&format=json

full work available at URL

19 September 2019

https://api.elsevier.com/content/article/PII:016781409190200Z?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/0167-8140(91)90200-Z

https://api.elsevier.com/content/article/PII:016781409190200Z?httpAccept=text/plain

3 December 2022

1 reference

https://api.crossref.org/works/10.1016/0167-8140(91)90200-Z

Radiotherapy and Oncology

3 December 2022

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1826961%20AND%20SRC:MED&resulttype=core&format=json

19 September 2019

volume

20 Suppl 1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1826961%20AND%20SRC:MED&resulttype=core&format=json

19 September 2019

page(s)

129-135

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1826961%20AND%20SRC:MED&resulttype=core&format=json

Phase I trial of the hypoxic cell radiosensitizer SR-2508: the results of the five to six week drug schedule

19 September 2019

cites work

1

1 reference

https://api.crossref.org/works/10.1016/0167-8140(91)90200-Z

Initial report of the phase I trial of the hypoxic cell radiosensitizer SR-2508

3 December 2022

2

1 reference

https://api.crossref.org/works/10.1016/0167-8140(91)90200-Z

Relationship between the neurotoxicity of the hypoxic cell radiosensitizer SR 2508 and the pharmacokinetic profile

3 December 2022

3

1 reference

https://api.crossref.org/works/10.1016/0167-8140(91)90200-Z

The value of adjuvant misonidazole in the definitive irradiation of advanced head and neck squamous cancer: An rtog pilot study (#78-02)

3 December 2022

4

1 reference

https://api.crossref.org/works/10.1016/0167-8140(91)90200-Z

Failure of misonidazole-sensitized radiotherapy to impact upon outcome among stage III-IV squamous cancers of the head and neck

3 December 2022

5

1 reference

https://api.crossref.org/works/10.1016/0167-8140(91)90200-Z

Radiotherapy and hyperbaric oxygen in head and neck cancer. Final report of first controlled clinical trial

3 December 2022

6

1 reference

https://api.crossref.org/works/10.1016/0167-8140(91)90200-Z

Radiotherapy and hyperbaric oxygen in head and neck cancer. Interim report of second clinical trial

3 December 2022

7

1 reference

https://api.crossref.org/works/10.1016/0167-8140(91)90200-Z

A phase I/II study of the hypoxic cell sensitizer misonidazole as an adjunct to high fractional dose radiotherapy in patients with unresectable squamous cell carcinoma of the head and neck: a RTOG randomized study (#79-04).

3 December 2022

8

1 reference

https://api.crossref.org/works/10.1016/0167-8140(91)90200-Z

Misonidazole combined with split-course radiotherapy in the treatment of invasive carcinoma of larynx and pharynx: report from the DAHANCA 2 study

3 December 2022

9

1 reference

https://api.crossref.org/works/10.1016/0167-8140(91)90200-Z

Clinical trials of hypoxic cell sensitizers

3 December 2022

10

1 reference

https://api.crossref.org/works/10.1016/0167-8140(91)90200-Z

Initial results of a phase I trial of continuous infusion SR 2508 (etanidazole): a radiation therapy oncology group study.

3 December 2022

12

1 reference

https://api.crossref.org/works/10.1016/0167-8140(91)90200-Z

3 December 2022

Identifiers

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1826961%20AND%20SRC:MED&resulttype=core&format=json

19 September 2019

1 reference